Tanta Pharmaceuticals

Tanta Pharmaceuticals is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics that target the Hippo signaling pathway. The company's primary focus is on inhibiting the YAP/TAZ transcriptional co-activators, which are frequently dysregulated in various cancers and fibrotic diseases. By leveraging its proprietary platform, Tanta aims to address high-unmet-need indications such as malignant mesothelioma and other solid tumors. The company was founded as a spin-off from the University of Virginia and is headquartered in Charlottesville, Virginia. Its research is centered on disrupting the protein-protein interactions essential for YAP/TAZ-driven oncogenesis.